In This Section
SNMMI Satellite Symposium: December 1, 2023
SNMMI Satellite Symposium:
PSMA-Targeted PET Imaging and Radioligand Therapy in the Management of Prostate Cancer: What Urologic Oncologists Need to Know
Date: December 1, 2023
Time: 7:00 - 8:00 am ET
Location: Omni Shoreham Hotel, 2500 Calvert St., NW, Washington, DC 20008
This complimentary breakfast event is being held as a satellite symposium at the 2024 Society of Urologic Oncology Annual Meeting. Pre-registration is encouraged but not required.
SNMMI has applied for 1.0 hour of AMA PRA Category 1 Credit for this in-person event.
SCHEDULE
6:45 am
Registration opens and breakfast is served
7:00 am
Educational Program
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly expressed by prostate cancer cells. In recent years, several small molecules targeting PSMA have been FDA approved for imaging men with localized high-risk or recurrent prostate cancer. Additionally, a beta-particle emitting radiotherapeutic agent targeting PSMA (177Lu-PSMA-617) has been approved for the treatment of men with castration-resistant prostate cancer.
In this session, co-led by a nuclear medicine physician and a genitourinary medical oncologist, we will discuss the basic principles of PET imaging and review the results from key trials of PSMA-targeted PET imaging. We will describe clinical scenarios in which PSMA-targeted PET imaging is indicated, with a focus on initial cancer staging, biochemical recurrence, management of oligometastatic disease, and selection of candidates for PSMA-targeted radioligand therapy. Additionally, we will discuss the importance of supporting PSMA-targeted PET imaging and radioligand therapy programs. Attendees should be able to return to their practices with the knowledge necessary to start ordering PSMA PET scans, to discuss test results with patients, and to discuss where radioligand therapy fits in the current treatment paradigm for patients with castration-resistant prostate cancer.
7:00 - 7:25 am
Nuclear Medicine Physician's Perspective
Frankis Almaguel, MD, PhD, Director, Molecular Imaging and Therapeutics Program, Loma Linda University Cancer Center
7:25 - 7:50 am
Genitourinary Oncologist's Perspective
Mehmet Asim Bilen, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
7:50 - 8:00 am
Q&A and Panel Discussion
CE Accreditation
CME Accreditation – AMA PRA Credits
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SNMMI has applied for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must complete the online assessment and evaluation available after the program.
This event is supported through a medical education grant from Lantheus Medical Imaging.